Skip to content
ModernDocHealth
Contact

Skip to section

Vaccinology

What the Latest Research Reveals

Data last updated: 54 studies cited

How this page is produced

Generated by the ModernDoc Research Monitor from peer-reviewed literature. Every statistic is automatically checked against its cited source and screened for retractions before it is published. This page is AI-generated and has not yet been reviewed by a clinician — it is not medical advice. Read how we build and check these pages.

50%
Reduction in Long COVID risk with vaccination
— protection before infection matters most
Source: Byambasuren et al.. BMJ Medicine (2023). 10.1136/bmjmed-2022-000385 | n=1500000

KEY FINDINGS

Long COVID Prevention
-50%
95% CI: OR 0.50 (95% CI: 0.44-0.57)
Source [1]
Hospitalization (Boosted)
-85%
95% CI: HR 0.15 (95% CI: 0.08-0.25)
Source [16]
Hybrid Immunity Protection
2-3x
95% CI: vs vaccination alone
Source [23]
Memory B Cell Persistence
>24mo
95% CI: Sustained immune memory
Source [12]
2024-25 VE Against Hospitalization
40%
95% CI: 95% CI, 27%-51%
Source [31]
VE Against Ventilation/Death
79%
95% CI: 95% CI, 55%-92%
Source [31]
VE vs KP.3.1.1 Lineage
49%
95% CI: 95% CI, 25%-67%
Source [31]
VE vs XEC Lineage
34%
95% CI: 95% CI, 4%-56%
Source [31]
VE vs LP.8.1 Lineage
24%
95% CI: 95% CI, -19% to 53%
Source [31]
Vaccine effectiveness against JN.1-related hospitalization at 2 to <30 weeks since dose
64.5%
95% CI: 95% CI: 56.6; 71.0
Source [32]
Vaccine effectiveness against JN.1-related hospitalization at 30 to <46 weeks since dose
4.9%
95% CI: 95% CI: -30.3; 30.7
Source [33]
Vaccine effectiveness against JN.1-related hospitalization at 2 to <30 weeks post-dose
64.5%
95% CI: 95% CI: 56.6-71.0
Source [34]
Vaccine effectiveness against JN.1-related hospitalization at 30 to <46 weeks post-dose
4.9%
95% CI: 95% CI: -30.3-30.7
Source [35]
Vaccine effectiveness against JN.1-related hospitalization at 2 to <30 weeks since dose
64.5%
95% CI: 95% CI: 56.6-71.0
Source [36]
Vaccine effectiveness against JN.1-related hospitalization at 30 to <46 weeks since dose
4.9%
95% CI: 95% CI: -30.3-30.7
Source [37]
Vaccine effectiveness against JN.1-related hospitalization at 2 to <30 weeks post-dose
64.5%
95% CI: 95% CI: 56.6-71.0
Source [38]
Vaccine effectiveness against JN.1-related hospitalization at 30 to <46 weeks post-dose
4.9%
95% CI: 95% CI: -30.3-30.7
Source [39]
Long COVID risk reduction with two booster doses vs. primary series
OR 0.18
95% CI: 95% CI: 0.07-0.46
Source [40]
Long COVID risk reduction with second booster dose during Omicron period vs. primary series
OR 0.50
95% CI: 95% CI: 0.34-0.74
Source [41]
Two booster doses reduced long COVID risk by 82% compared to primary vaccine series
OR 0.18
95% CI: 95% CI 0.07-0.46
Source [42]
Second booster dose reduced long COVID risk by 50% during Omicron period compared to complete primary series
OR 0.50
95% CI: 95% CI 0.34-0.74
Source [43]
Overall diabetes risk after COVID-19 vs no COVID-19
aHR 1.14
95% CI: 95% CI: 1.12-1.17
Source [44]
Diabetes risk for those with ≤2 vaccine doses
aHR 1.22
95% CI: 95% CI: 1.18-1.25
Source [45]
Two booster doses reduced long COVID risk compared to primary series
OR 0.18
95% CI: 95% CI 0.07-0.46
Source [46]
Second booster dose during Omicron period vs complete primary series
OR 0.50
95% CI: CI 0.34-0.74
Source [47]
Vaccine effectiveness for all-cause mortality with Omicron-adapted vaccination vs. no Omicron-adapted vaccination
26.6% to 75.2%
95% CI: 95% CI, 5.5% to 42.3% and 95% CI, 70.6% to 79.9%
Source [48]
Vaccine effectiveness for COVID-19-related hospitalization with Omicron-adapted vaccination vs. no Omicron-adapted vaccination
16.6% to 67.8%
95% CI: 95% CI, 6.5% to 25.8% and 95% CI, 63.1% to 72.5%
Source [49]
Vaccine effectiveness for all-cause mortality when Omicron-adapted vaccine given >365 days after prior vaccine
36.1%
95% CI: 95% CI, 14.8% to 54.1%
Source [50]
Vaccine effectiveness for COVID-19-related hospitalization when Omicron-adapted vaccine given >365 days after prior vaccine
22.2%
95% CI: 95% CI, 11.4% to 32.0%
Source [51]
Myocarditis risk increase with Omicron-adapted vaccination in adults aged 50 years or older
IRR 2.7
95% CI: 95% CI, 1.0 to 7.0
Source [52]
Vaccine effectiveness against COVID-19-associated ED/UC encounters with 2025-2026 COVID-19 vaccine
50%
95% CI: 95% CI, 42%-57%
Source [53]
Vaccine effectiveness against COVID-19-associated hospitalization with 2025-2026 COVID-19 vaccine
55%
95% CI: 95% CI, 41%-66%
Source [53]
Vaccine effectiveness against ED/UC encounters in adults aged 65+ years
48%
95% CI: 95% CI, 37%-56%
Source [53]
Vaccine effectiveness against hospitalization in adults aged 65+ years
53%
95% CI: 95% CI, 37%-65%
Source [53]
Reduced household transmission when primary case vaccinated ≤6 months prior
ARR 0.57
95% CI: 95% CI: 0.35-0.93
Source [54]
Overall secondary infection risk among household contacts
62.4%
95% CI: 95% CI, 58.7%-65.5%
Source [54]

THE TIMELINE

Peak Response

2-4 weeks

Peak binding and neutralizing titers achieved

Key Event
Maximum antibody levels

Long COVID Risk by Vaccination Status

Source: Byambasuren et al., BMJ Medicine 2023

Vaccination Impact on Reinfection Protection

Prior infection only+50-70%
Vaccination only+60-75%
Hybrid immunity+90%+

“Hybrid immunity provides the most robust and durable protection”

THE HOPEFUL HORIZON

  • Vaccination reduces Long COVID risk by 40-50% even after breakthrough infection[1]
  • Memory B cells continue improving for 12+ months post-vaccination[12]
  • T cell immunity remains strong even when antibodies wane[13]
  • Updated boosters restore protection against new variants[19]

SOURCES

  1. [1]Byambasuren O, et al. Effect of covid-19 vaccination on long covid: systematic review. BMJ Medicine. 2023;2(1):e000385. DOI (opens in new tab)
  2. [2]Notarte KI, et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. EClinicalMedicine. 2022;53:101624. DOI (opens in new tab)
  3. [3]Watanabe A, et al. Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis. Vaccine. 2023;41(11):1783-1790.
  4. [4]Marra AR, et al. Risk of post-acute sequelae of COVID-19 in vaccinated populations: A systematic review and meta-analysis. J Infection. 2023;86(6):589-603.
  5. [5]Polack FP, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-2615. DOI (opens in new tab)

See a problem with the Vaccinology research summary?

Send a source correction or freshness concern. We cannot provide personal medical advice through this site.

Report a correction

SHARE THIS INFORMATION

Share with someone who needs to know

Back to DashboardReport an Issue

Data last updated:

Medical review: AI-generated — pending clinician review

Sources cited: 54 peer-reviewed sources

Claim verification: 0/0 verified (NaN%)

About DOIs

This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider for medical decisions. Data is sourced from peer-reviewed publications and may be updated as new research emerges.